13F Holdings
中文EN

MOLN MOLECULAR PARTNERS AG IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1745114 · Reporting currency CHF · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-29.4%
TTM net income YoY12.8%
TTM EPS YoY15.9%
Revenue 3-yr CAGR-20.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,231.7%
Net margin-1,087.4%
FCF margin-1,206.3%
EBITDA margin-1,184.1%

Returns

ROE-34.0%
ROA-30.3%
ROIC (approx.)-51.8%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets10.7%
Debt / equity0.00x
Current ratio14.31x
Interest coverage-1,610.97x

Cash quality & payout

Operating cash flow / net income1.10x
Accruals ratio2.9%
Payout ratio—
Capex / revenue14.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CHF FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue04.97M7.04M189.60M9.75M
R&D expense40.19M48.60M48.78M50.75M55.72M
SG&A expense15.24M17.58M19.36M22.24M17.45M
Operating income-58.12M-61.22M-61.11M116.61M-63.42M
Interest expense5.05M38,0005.16M619,000556,000
Pretax income-61.65M-54.04M-61.98M117.85M-63.78M
Income tax2,0002,000002,000
Net income-61.65M-54.04M-61.98M117.85M-63.78M
EBITDA-55.98M-58.85M-58.69M119.00M-60.85M
EPS (basic)-1.65-1.59-1.893.63-2.06
EPS (diluted)-1.65-1.59-1.893.54-2.06
Weighted avg. shares (diluted)37.27M34.03M32.77M33.27M31.01M
Balance sheet
Cash & equivalents82.65M63.87M67.31M87.95M71.81M
Short-term investments10.40M85.56M119.58M161.20M61.00M
Receivables1.83M2.32M1.95M1.02M25.65M
Current assets96.88M154.28M192.46M254.75M164.19M
PP&E, netmay include right-of-use assets (IFRS)5.23M4.20M5.68M7.24M8.15M
Intangibles2,00049,000212,000271,000331,000
Total assets102.11M158.53M198.35M262.26M172.67M
Current liabilities11.03M10.79M14.42M17.25M46.87M
Total liabilities21.77M16.89M21.92M27.09M65.38M
Shareholders' equity80.33M141.64M176.43M235.17M107.29M
Shares outstanding40.37M40.36M36.35M36.04M32.29M
Cash flow statement
Operating cash flow-51.26M-59.25M-59.01M118.57M-90.95M
Capital expenditure714,000705,000575,0001.18M933,000
Free cash flow-51.97M-59.95M-59.58M117.39M-91.89M
Investing cash flow72.55M40.49M44.64M-101.12M-22.24M
Financing cash flow-1.15M14.43M-1.17M-1.57M50.58M
Depreciation & amortization2.14M2.37M2.42M2.39M2.56M
Stock-based compensation4.42M4.11M5.21M5.09M4.08M
Share buybacks—00631,0000

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.